ClinicalTrials.gg
RecruitingNCT07652905CAREMM-011Updated Sep 18, 2026

CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia

A Phase 2 interventional study of CM336 and Isatuximab in Plasma Cell Leukemia (PCL), sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Leukemia, Plasma Cell with a site in China — 17 open to participants now, 18 under way, none of them phase 3. Leukemia, Plasma Cell · China.

Planned enrollment
8th of 19
24 · median 24
Started
2026
with 2 others
Phase 2
7 of 20
5 open now
Primary completion
2029-06
later than 15 of 17 live
Registered
19th of 20
by date
Lead sponsor
8 of 20
Institute of Hematology & Blood Diseases Hospital, China

Among the 20 studies in Leukemia, Plasma Cell with a site in China, this one is the 8th largest by planned enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2026, is one of 7 in phase 2, reaches primary completion later than 15 of the 17 other live ones, and was the 19th registered.

Leukemia, Plasma Cell

60 studies on the registry are indexed under Leukemia, Plasma Cell; 33 are open to participants now.

Browse Leukemia, Plasma Cell studies →

Open to participants now

17 of the 20 studies in Leukemia, Plasma Cell with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Leukemia, Plasma Cell studies recruiting now, 12 (41%) set no upper age limit and 13 (45%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Leukemia, Plasma Cell with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether CM336, a BCMA/CD3 bispecific antibody, can improve treatment outcomes when combined with isatuximab, lenalidomide, and bortezomib in adults with newly diagnosed primary plasma cell leukemia (pPCL). The study will also evaluate the safety of this treatment combination.

The main questions it aims to answer are:

How many participants achieve minimal residual disease (MRD) negativity after 9 treatment cycles? What side effects occur during treatment with CM336 combined with isatuximab, lenalidomide, and bortezomib? How many participants respond to treatment, and how long do those responses last? How long do participants remain free from disease progression, and how long do they survive after starting treatment? All participants will receive the study treatment. There is no comparison group in this study.

Participants will:

Receive CM336 by subcutaneous injection together with isatuximab, lenalidomide, and bortezomib in 28-day treatment cycles.

Undergo regular blood tests, bone marrow examinations, and disease assessments to monitor treatment response and safety.

Have stem cells collected after the first 3 treatment cycles if appropriate. Continue treatment for up to 18 cycles, followed by maintenance treatment with isatuximab and lenalidomide until disease progression, unacceptable toxicity, withdrawal of consent, or investigator decision.

Be monitored throughout the study for side effects.

03

Conditions studied

  • Plasma Cell Leukemia (PCL)

Browse trials for

Keywords

  • BCMA/CD3 bispecific antibody
  • CM336
  • Primary plasma cell leukemia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand and voluntarily sign a written form (ICF).
  2. Age 18 to 75 years.
  3. Newly diagnosed primary plasma cell leukemia (pPCL) according to International Myeloma Working Group (IMWG) criteria, defined as either:

    • ≥5% circulating plasma cells on peripheral blood smear; or
    • Absolute circulating plasma cell count >2 × 10⁹/L.

    Patients who have received no more than one prior cycle of anti-myeloma therapy before enrollment are eligible.

  4. , defined by at least one of the following:

    • Serum M-protein ≥10 g/L as measured by serum protein electrophoresis (SPEP); for IgA or IgD myeloma, quantitative IgA or IgD levels may be used instead;
    • Urine M-protein ≥200 mg/24 hours;
    • If neither serum nor urine M-protein meets the above criteria, involved serum free light chain (FLC) ≥100 mg/L with an abnormal serum FLC ratio (normal range: 0.26-1.65).
  5. Adequate hepatic function, defined as:

    • Total \<1.5 × (ULN), except for participants with Gilbert syndrome, who must have total bilirubin \<3 × ULN;
    • (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN.
  6. Adequate renal function, defined as ≥30 mL/min, calculated using the Cockcroft-Gault formula.
  7. Adequate hematologic function within 7 days prior to enrollment, defined as:

    • White blood cell (WBC) count ≥1.5 × 10⁹/L;
    • (ANC) ≥1.0 × 10⁹/L;
    • ≥70 g/L;
    • count ≥50 × 10⁹/L;

    Alternatively, eligibility may be determined by the investigator based on clinical judgment.

  8. Participants receiving hematopoietic growth factor support, including erythropoietin, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), or thrombopoietic agents, must have a of at least 2 weeks between the last administration of growth factor support and screening assessments.
  9. Participants receiving blood product transfusions must meet the following requirements:

    • At least 2 weeks between the last red blood cell (RBC) transfusion and hemoglobin assessment at screening;
    • At least 1 week between the last platelet transfusion and platelet count assessment at screening.
  10. Able and willing to receive protocol-recommended prophylactic anticoagulation therapy.
  11. Female participants of must have a negative serum pregnancy test at screening and agree to use effective from the time of signing the informed consent form, throughout study treatment, and for at least 3 months after the last dose of study treatment.

Male participants, including those who have undergone vasectomy, must agree to use condoms during sexual intercourse with women of childbearing potential and must not plan to father a child from the time of signing informed consent through 3 months after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), Waldenström macroglobulinemia, POEMS syndrome, amyloidosis, or secondary plasma cell leukemia.
  2. Central nervous system (CNS) involvement or clinical evidence of .
  3. Known intolerance, , allergy, or to CM336, isatuximab, bortezomib or lenalidomide.
  4. Severe and/or uncontrolled cardiovascular disease, including:

    Unstable angina; Symptomatic congestive heart failure; Myocardial infarction within 6 months prior to enrollment; Severe and uncontrolled cardiac arrhythmias; Any other cardiovascular or cerebrovascular condition deemed by the investigator to make participation inappropriate.

  5. Active infection, including:

    (HIV) infection; Active infection (HBV DNA positive); Active infection (HCV RNA positive); Active or latent syphilis infection (positive Treponema pallidum antibody test); Active pulmonary tuberculosis, as evidenced by chest imaging or other relevant assessments within 3 months prior to screening or during the screening period; Any other infection considered by the investigator to make participation inappropriate.

  6. Concurrent active or any serious concomitant disease that, in the investigator's judgment, could compromise participant safety or interfere with study participation.
  7. Pregnant or breastfeeding women.
  8. Estimated of less than 6 months.
  9. Active gastrointestinal disorders that may impair the participant's ability to swallow oral medication or may interfere with the absorption of study treatment.
  10. Major surgery within 2 weeks prior to enrollment (e.g., surgery requiring general anesthesia), incomplete recovery from prior surgery, or planned major surgery during study participation. Kyphoplasty and vertebroplasty are not considered major surgery. Participants undergoing procedures under local anesthesia may be eligible.
  11. Receipt of a within 4 weeks before the first dose of study treatment.
  12. Any active severe psychiatric disorder, medical condition, symptom, or other circumstance that, in the investigator's judgment, may interfere with treatment, protocol compliance, or the ability to provide .
  13. Inability or unwillingness to provide written informed consent.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    CM336 plus Isa-VR

    Enrolled patients will receive 18 cycles of therapy with CM336 in combination with isatuximab, bortezomib and lenalidomide

    Drug: CM336 · Drug: Isatuximab · Drug: Bortezomib · Drug: Lenalidomide

Interventions

  • DrugCM336

    CM336 is administered subcutaneously (SC) using a step-up dosing regimen, followed by a target dose of 160 mg. During Cycle 1, CM336 is administered weekly; from Cycle 2 through Cycle 18, it is administered every 4 weeks.

  • Isatuximab is administered intravenously (IV) at 10 mg/kg. It is given weekly during Cycle 1, every 2 weeks during Cycles 2-12, and every 4 weeks during Cycles 13-18.

  • Bortezomib is administered subcutaneously (SC) at 1.3 mg/m² once weekly during Cycles 1-18.

  • Lenalidomide is administered orally at 25 mg once daily on Days 1-21 of each 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Minimal residual disease (MRD) negative rate

    Time frame: After 9 cycles (each cycle is 28 days)

Secondary outcomes

  1. Incidence and severity of adverse events (AEs)

    Time frame: From the first dose of CM336 through 30 days after the last dose of CM336, up to approximately 18 months.

  2. Duration of MRD negativity

    Time frame: From the date of first documented MRD negativity until disease progression, death, or end of follow-up, whichever occurs first, assessed up to approximately 36 months.

  3. Hematological Overall Response Rate (ORR)

    Time frame: Up to 18 treatment cycles, each cycle is 28 days

  4. Progression-free survival (PFS)

    Time frame: From the first dose of study treatment until the date of first documented disease progression or death from any cause, whichever occurs first, up to approximately 36 months.

  5. Overall survival (OS)

    Time frame: From the first dose of study treatment until death from any cause, up to approximately 36 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Jun 2029, 33 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Jun 17, 2026
StartEst.
Sep 15, 2026
Primary completionEst.
Jun 30, 2029
CompletionEst.
Dec 30, 2031
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07652905
Responsible party
Sponsor
First posted
Jun 17, 2026
Start date
Sep 15, 2026 (estimated)
Primary completion
Jun 30, 2029 (estimated)
Completion
Dec 30, 2031 (estimated)
Last update
Sep 18, 2026

Study contacts

Gang An, PhD & MD
Contact
angang@ihcams.ac.cn
+86 13502181109

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CM336

Start the discussion